HSIC Quote, Financials, Valuation and Earnings

Standard BioTools has a net margin of 3.12% compared to Henry Schein's net margin of -59.9%. Henry Schein's return on equity of 6.21% beat Standard BioTools's return on equity of -48.03%.

Henry Schein has a consensus price target of $74.83, signalling upside risk potential of 9.17%. On the other hand Standard BioTools has an analysts' consensus of -- which suggests that it could grow by 76.19%. Given that Standard BioTools has higher upside potential than Henry Schein, analysts believe Standard BioTools is more attractive than Henry Schein.

Henry Schein has a beta of 0.892, which suggesting that the stock is 10.818% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.572, suggesting its more volatile than the S&P 500 by 57.231%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

Henry Schein quarterly revenues are $3.2B, which are larger than Standard BioTools quarterly revenues of $45M. Henry Schein's net income of $99M is higher than Standard BioTools's net income of -$26.9M. Notably, Henry Schein's price-to-earnings ratio is 28.09x while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.71x versus 3.14x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of 3.12% compared to Henry Schein's net margin of -11.09%. Henry Schein's return on equity of 6.21% beat LENSAR's return on equity of -56.16%.

Henry Schein has a consensus price target of $74.83, signalling upside risk potential of 9.17%. On the other hand LENSAR has an analysts' consensus of -- which suggests that it could grow by 26.58%. Given that LENSAR has higher upside potential than Henry Schein, analysts believe LENSAR is more attractive than Henry Schein.

Henry Schein has a beta of 0.892, which suggesting that the stock is 10.818% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

Henry Schein quarterly revenues are $3.2B, which are larger than LENSAR quarterly revenues of $13.5M. Henry Schein's net income of $99M is higher than LENSAR's net income of -$1.5M. Notably, Henry Schein's price-to-earnings ratio is 28.09x while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.71x versus 2.03x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.

Patterson Companies has a net margin of 3.12% compared to Henry Schein's net margin of 1.6%. Henry Schein's return on equity of 6.21% beat Patterson Companies's return on equity of 15.7%.

Henry Schein has a consensus price target of $74.83, signalling upside risk potential of 9.17%. On the other hand Patterson Companies has an analysts' consensus of $29.68 which suggests that it could fall by -3.65%. Given that Henry Schein has higher upside potential than Patterson Companies, analysts believe Henry Schein is more attractive than Patterson Companies.

Henry Schein has a beta of 0.892, which suggesting that the stock is 10.818% less volatile than S&P 500. In comparison Patterson Companies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.422%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Patterson Companies offers a yield of 3.38% to investors and pays a quarterly dividend of $0.26 per share. Henry Schein pays -- of its earnings as a dividend. Patterson Companies pays out 52.89% of its earnings as a dividend. Patterson Companies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Henry Schein quarterly revenues are $3.2B, which are larger than Patterson Companies quarterly revenues of $1.7B. Henry Schein's net income of $99M is higher than Patterson Companies's net income of $26.8M. Notably, Henry Schein's price-to-earnings ratio is 28.09x while Patterson Companies's PE ratio is 18.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.71x versus 0.42x for Patterson Companies. Usually stocks with elevated PS ratios are considered overvalued.

Zomedica has a net margin of 3.12% compared to Henry Schein's net margin of -95.71%. Henry Schein's return on equity of 6.21% beat Zomedica's return on equity of -27.17%.

Henry Schein has a consensus price target of $74.83, signalling upside risk potential of 9.17%. On the other hand Zomedica has an analysts' consensus of -- which suggests that it could grow by 80.9%. Given that Zomedica has higher upside potential than Henry Schein, analysts believe Zomedica is more attractive than Henry Schein.

Henry Schein has a beta of 0.892, which suggesting that the stock is 10.818% less volatile than S&P 500. In comparison Zomedica has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.877%.

Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zomedica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. Zomedica pays out -- of its earnings as a dividend.

Henry Schein quarterly revenues are $3.2B, which are larger than Zomedica quarterly revenues of $7M. Henry Schein's net income of $99M is higher than Zomedica's net income of -$6.7M. Notably, Henry Schein's price-to-earnings ratio is 28.09x while Zomedica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.71x versus 5.07x for Zomedica. Usually stocks with elevated PS ratios are considered overvalued.